---
title: "04:28 ETALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294932617.md"
description: "Schall, Brown & Schwartz LLP is investigating Alnylam Pharmaceuticals (NASDAQ: ALNY) for potential securities law violations. The probe examines whether the company issued misleading statements or failed to disclose material information regarding its Q2 2026 results and lowered TTR product sales guidance. Following this announcement on July 30, 2026, Alnylam's shares dropped nearly 28.4%. Investors who suffered losses are encouraged to contact the firm to discuss their rights."
datetime: "2026-08-05T08:28:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294932617.md)
  - [en](https://longbridge.com/en/news/294932617.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294932617.md)
generator: "portal-rs"
---

# 04:28 ETALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

, /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of the securities laws.

**INVESTIGATION DETAILS:** The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Alnylam announced its Q2 2026 financial results on July 30, 2026. The Company revealed it had "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." Based on this news, shares of Alnylam fell by almost 28.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at \[email protected\]

**WHY SBS?** Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

**CONTACT:**

Schall, Brown & Schwartz LLP  
Brian Schall, Esq.,  
Andrew Brown, Esq.,  
David Schwartz, Esq.,  
www.schallfirm.com  
Office: 310-301-3335  
\[email protected\]

SOURCE Schall, Brown & Schwartz LLP

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [16:00 ET(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm](https://longbridge.com/en/news/296687484.md)
- [16:58 ETInvestor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm](https://longbridge.com/en/news/296031373.md)
- [04:31 ETCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law](https://longbridge.com/en/news/296588659.md)
- [02:14 ETFutu Holdings Limited Investor Alert: Contact SBS by August 25, 2026 for Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/296574483.md)
- [04:21 ETPhotronics, Inc. Investor Alert: Contact SBS by September 4, 2026 for Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/296587330.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**